Reported 1 day ago
Stifel has reiterated a Buy rating for Dianthus Therapeutics, Inc. (NASDAQ:DNTH), setting a price target of $52.00, which suggests a potential upside of 186.3% from its current price of $18.02. The firm emphasizes the company's sound financials and the anticipated Phase 2 trial results for DNTH103, a drug for myasthenia gravis expected in September 2025. Positive trial outcomes could pave the way for further development in related conditions, marking a strong investment opportunity in the biotech sector.
Source: YAHOO